keyword
MENU ▼
Read by QxMD icon Read
search

Human Factors in Patient Safety

keyword
https://www.readbyqxmd.com/read/29042806/feeding-filaggrin-effects-of-l-histidine-supplementation-in-atopic-dermatitis
#1
Siao Pei Tan, Simon B Brown, Christopher Em Griffiths, Richard B Weller, Neil K Gibbs
Atopic dermatitis (AD), also known as eczema, is one of the most common chronic skin conditions worldwide, affecting up to 16% of children and 10% of adults. It is incurable and has significant psychosocial and economic impacts on the affected individuals. AD etiology has been linked to deficiencies in the skin barrier protein, filaggrin. In mammalian skin, l-histidine is rapidly incorporated into filaggrin. Subsequent filaggrin proteolysis releases l-histidine as an important natural moisturizing factor (NMF)...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/29040918/tumor-cryoablation-in-combination-with-natural-killer-cells-therapy-and-herceptin-in-patients-with-her2-overexpressing-recurrent-breast-cancer
#2
Shuzhen Liang, Lizhi Niu, Kecheng Xu, Xiaohua Wang, Yingqing Liang, Mingjie Zhang, Jibing Chen, Mao Lin
In this study, we investigated the clinical benefits of a combination of tumor cryoablation with natural killer (NK) cells therapy and Herceptin for human epidermal growth factor (HER) 2-overexpressing recurrent breast cancer. From May 2015 to May 2016, 48 patients who met the enrollment criteria were assigned to three groups (n=16): cryoablation group (group I), cryoablation-NK cells therapy group (group II) and cryoablation-NK cells therapy-Herceptin group (group III). Safety and short-term effects were evaluated...
October 13, 2017: Molecular Immunology
https://www.readbyqxmd.com/read/29033605/onabotulinum-toxin-a-in-the-treatment-of-chronic-migraine-patient-selection-and-special-considerations
#3
REVIEW
Piero Barbanti, Patrizia Ferroni
Discovered by serendipity, onabotulinum toxin A (BoNT-A) is the only US Food and Drug Administration-approved treatment for the prevention of chronic migraine (CM), one of the most disabling and burdensome human conditions. Its efficacy, safety and tolerability, proved by the largest and longest migraine therapeutic trial (the Phase III Research Evaluating Migraine Prophylaxis Therapy program [PREEMPT]), have been replicated by various real-life studies also in the presence of medication overuse. The benefit of BoNT-A prophylaxis is likely due to its ability to counteract peripheral and central nociceptive sensitization through reversible chemical denervation of pericranial sensitive afferents...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/29028917/comparative-usability-of-modern-anaesthesia-ventilators-a-human-factors-study
#4
J Spaeth, T Schweizer, A Schmutz, H Buerkle, S Schumann
Background: The anaesthesia ventilator represents the key equipment for intraoperative respiratory care. Improper operation of this device may threaten a patient's health. A self-explanatory interface facilitates handling and decreases the risk of operating errors. This study systematically evaluates the usability of user interfaces in four modern anaesthesia ventilators. Methods: Twenty naïve operators were asked to execute 20 tasks on each of four different anaesthesia ventilators (Avance CS2™, GE Healthcare; Flow-i™, Maquet; and Perseus™ and Primus™, Dräger) in a randomized order...
October 3, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29024416/review-article-a-systematic-review-of-emergency-department-incident-classification-frameworks
#5
REVIEW
Matthew Murray, Sally McCarthy
As in any part of the hospital system, safety incidents can occur in the ED. These incidents arguably have a distinct character, as the ED involves unscheduled flows of urgent patients who require disparate services. To aid understanding of safety issues and support risk management of the ED, a comparison of published ED specific incident classification frameworks was performed. A review of emergency medicine, health management and general medical publications, using Ovid SP to interrogate Medline (1976-2016) was undertaken to identify any type of taxonomy or classification-like framework for ED related incidents...
October 11, 2017: Emergency Medicine Australasia: EMA
https://www.readbyqxmd.com/read/29023613/comparative-study-of-rhpdgf-bb-plus-equine-derived-bone-matrix-versus-rhpdgf-bb-plus-%C3%AE-tcp-in-the-treatment-of-periodontal-defects
#6
Ji-Young Lee, Hei-Jin Na, Hyun-Min Kim, Sang-Cheol Lee, Jue-Yeon Lee, Chong-Pyoung Chung, Yang-Jo Seol, Yoon Jeong Park
The purpose of this study was to evaluate the efficacy and safety of equine-derived bone matrix as a carrier for recombinant human platelet-derived growth factor BB (rhPDGF-BB) versus beta-tricalcium phosphate (β-TCP) for the treatment of intraosseous periodontal defects in adult patients. This study was performed on 32 adults with advanced periodontal disease. Eligible subjects were randomized in 1:1 ratio into a test (rhPDGF-BB-coated equine-derived bone matrix) or control group (rhPDGF-BB-coated β-TCP)...
November 2017: International Journal of Periodontics & Restorative Dentistry
https://www.readbyqxmd.com/read/29022084/exposure-response-analyses-of-trastuzumab-emtansine-in-patients-with-her2-positive-advanced-breast-cancer-previously-treated-with-trastuzumab-and-a-taxane
#7
Chunze Li, Bei Wang, Shang-Chiung Chen, Russell Wada, Dan Lu, Xin Wang, Daniel Polhamus, Jonathan French, Shweta Vadhavkar, Alexander Strasak, Melanie Smitt, Amita Joshi, Meghna Samant, Angelica Quartino, Jin Jin, Sandhya Girish
PURPOSE: In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus capecitabine plus lapatinib (control) in previously treated human epidermal growth factor receptor 2-positive advanced breast cancer. Using EMILIA data, we evaluated the T-DM1 exposure-response relationship. METHODS: Exposure-response relationships were examined with four exposure metrics [model-predicted and observed minimum concentration (C min) and area under the concentration-time curve from time zero to day 21 of T-DM1 at cycle 1] and multiple efficacy (OS, PFS, objective response rate) and safety (grade ≥ 3 adverse events, grade ≥ 3 thrombocytopenia, grade ≥ 3 hepatotoxicity) endpoints...
October 11, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28990424/an-inducible-promoter-responsive-to-different-porphyrinogenic-stimuli-improves-gene-therapy-vectors-for-acute-intermittent-porphyria
#8
Irantzu Serrano, Ana Sampedro, Manuel Alegre, Rafael Enriquez de Salamanca, Pedro Berraondo, Antonio Fontanellas
Porphobilinogen deaminase (PBGD)-gene therapy represents a promising therapeutic option for acute intermittent porphyria (AIP) patients suffering recurrent acute attacks. The first-in-human phase 1 clinical trial confirmed the safety and tolerability of AAV-AAT-PBGD gene therapy but higher doses and/or more efficient vectors are needed to achieve therapeutic expression of the transgene. We assayed the insertion into the promoter of a short enhancer element able to induce transgene expression during the exposure to endogenous and exogenous stimuli related to the pathology of the disease...
October 7, 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/28984010/safety-and-dose-dependency-of-eptacog-beta-activated-in-a-dose-escalation-study-of-non-bleeding-congenital-haemophilia-a-or-b-patients-with-or-without-inhibitors
#9
J Ducore, J B Lawrence, M Simpson, L Boggio, A Bellon, J Burggraaf, J Stevens, M Moerland, J Frieling, J Reijers, M Wang
INTRODUCTION: Varying initial doses of activated eptacog beta (recombinant human FVIIa, rhFVIIa) may provide therapeutic options when treating bleeding in patients with congenital haemophilia who have developed inhibitory antibodies to factor VIII (FVIII) or factor IX (FIX). This study evaluated escalated doses of a new rhFVIIa product as a prelude to selecting the doses for clinical efficacy evaluation in haemophilia patients. AIM: To assess the safety, pharmacokinetics, and laboratory pharmacodynamics of 3 doses of rhFVIIa in non-bleeding patients with congenital haemophilia A or B with or without inhibitors...
October 5, 2017: Haemophilia: the Official Journal of the World Federation of Hemophilia
https://www.readbyqxmd.com/read/28982740/phase-ii-evaluation-of-anti-madcam-antibody-pf-00547659-in-the-treatment-of-crohn-s-disease-report-of-the-opera-study
#10
William J Sandborn, Scott D Lee, Dino Tarabar, Edouard Louis, Maria Klopocka, Jochen Klaus, Walter Reinisch, Xavier Hébuterne, Dong-Il Park, Stefan Schreiber, Satyaprakash Nayak, Alaa Ahmad, Anindita Banerjee, Lisa S Brown, Fabio Cataldi, Kenneth J Gorelick, John B Cheng, Mina Hassan-Zahraee, Robert Clare, Geert R D'Haens
OBJECTIVE: This phase II, randomised, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule (MAdCAM) to selectively reduce lymphocyte homing to the intestinal tract, in patients with moderate-to-severe Crohn's disease (CD). DESIGN: Eligible adults were aged 18-75 years, with active moderate-to-severe CD (Crohn's Disease Activity Index (CDAI) 220-450), a history of failure or intolerance to antitumour necrosis factor and/or immunosuppressive agents, high-sensitivity C reactive protein >3...
October 5, 2017: Gut
https://www.readbyqxmd.com/read/28980365/technical-rationality-and-the-decentring-of-patients-and-care-delivery-a-critique-of-unavoidable-in-the-context-of-patient-harm
#11
Marie Hutchinson, Debra Jackson, Stacey Wilson
In recent decades, debate on the quality and safety of healthcare has been dominated by a measure and manage administrative rationality. More recently, this rationality has been overlaid by ideas from human factors, ergonomics and systems engineering. Little critical attention has been given in the nursing literature to how risk of harm is understood and actioned, or how patients can be subjectified and marginalised through these discourses. The problem of assuring safety for particular patient groups, and the dominance of technical forms of rationality, has seen the word 'unavoidable' used in connection with intractable forms of patient harm...
October 4, 2017: Nursing Inquiry
https://www.readbyqxmd.com/read/28970457/pharmacists-attitudes-and-perceived-barriers-to-human-papillomavirus-hpv-vaccination-services
#12
Tessa J Hastings, Lindsey A Hohmann, Stuart J McFarland, Benjamin S Teeter, Salisa C Westrick
Use of non-traditional settings such as community pharmacies has been suggested to increase human papillomavirus (HPV) vaccination uptake and completion rates. The objectives of this study were to explore HPV vaccination services and strategies employed by pharmacies to increase HPV vaccine uptake, pharmacists' attitudes towards the HPV vaccine, and pharmacists' perceived barriers to providing HPV vaccination services in community pharmacies. A pre-piloted mail survey was sent to 350 randomly selected community pharmacies in Alabama in 2014...
August 7, 2017: Pharmacy (Basel, Switzerland)
https://www.readbyqxmd.com/read/28969087/efficacy-and-safety-of-t-dm1-in-the-common-practice-of-her2-advanced-breast-cancer-setting-a-multicenter-study
#13
Alessandra Fabi, Michelino De Laurentiis, Michele Caruso, Enrichetta Valle, Luca Moscetti, Daniele Santini, Katia Cannita, Luisa Carbognin, Mariangela Ciccarese, Rosalba Rossello, Grazia Arpino, Vita Leonardi, Filippo Montemurro, Nicla La Verde, Daniele Generali, Alberto Zambelli, Giuseppa Scandurra, Michelangelo Russillo, Ida Paris, Anna Maria D'Ottavio, Gianfranco Filippelli, Marianna Giampaglia, Simonetta Stani, Agnese Fabbri, Daniele Alesini, Daniela Cianniello, Diana Giannarelli, Francesco Cognetti
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28968163/monarch-3-abemaciclib-as-initial-therapy-for-advanced-breast-cancer
#14
Matthew P Goetz, Masakazu Toi, Mario Campone, Joohyuk Sohn, Shani Paluch-Shimon, Jens Huober, In Hae Park, Olivier Trédan, Shin-Cheh Chen, Luis Manso, Orit C Freedman, Georgina Garnica Jaliffe, Tammy Forrester, Martin Frenzel, Susana Barriga, Ian C Smith, Nawel Bourayou, Angelo Di Leo
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28965727/proteome-wide-map-of-targets-of-t790m-egfr-directed-covalent-inhibitors
#15
Sherry Niessen, Melissa M Dix, Sabrina Barbas, Zachary E Potter, Shuyan Lu, Oleg Brodsky, Simon Planken, Douglas Behenna, Chau Almaden, Ketan S Gajiwala, Kevin Ryan, RoseAnn Ferre, Michael R Lazear, Matthew M Hayward, John C Kath, Benjamin F Cravatt
Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first- and second-generation EGFR inhibitors. However, these patients often relapse due to a secondary, drug-resistant mutation in EGFR whereby the gatekeeper threonine is converted to methionine (T790M). Several third-generation EGFR inhibitors have been developed that irreversibly inactivate T790M-EGFR while sparing wild-type EGFR, thus reducing epithelium-based toxicities...
September 18, 2017: Cell Chemical Biology
https://www.readbyqxmd.com/read/28963915/efficacy-and-safety-of-subcutaneous-trastuzumab-and-intravenous-trastuzumab-as-part-of-adjuvant-therapy-for-her2-positive-early-breast-cancer-final-analysis-of-the-randomised-two-cohort-prefher-study
#16
X Pivot, S Verma, L Fallowfield, V Müller, M Lichinitser, V Jenkins, A Sánchez Muñoz, Z Machackova, S Osborne, J Gligorov
AIM: To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166). PATIENTS AND METHODS: Post surgery and post chemotherapy in the (neo)adjuvant setting, patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer were randomised to receive four cycles of the subcutaneous form of trastuzumab (Herceptin(®) SC [H SC] via single-use injection device [Cohort 1] or delivery via a hand-held syringe from an SC Vial [Cohort 2]; 600 mg fixed dose) followed by four of the intravenous form of trastuzumab (Herceptin(®) [H IV]; 8 mg/kg loading, 6 mg/kg maintenance doses) in the adjuvant setting or vice versa every 3 weeks...
September 27, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28963670/development-of-an-lc-ms-ms-method-with-protein-g-purification-strategy-for-quantifying-bevacizumab-in-human-plasma
#17
Huai-Hsuan Chiu, I-Lin Tsai, Yen-Shen Lu, Ching-Hung Lin, Ching-Hua Kuo
Biopharmaceutical products such as protein drugs and monoclonal antibodies (mAb) are currently of great interest with monoclonal antibody drugs being one of the fastest growing categories of biopharmaceutical products. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) has gained high interest for measuring mAb drugs in biological samples in recent years due to its high selectivity. Bevacizumab is a humanized immunoglobulin G (IgG) mAb drug against human vascular endothelial cell growth factor A (VEGF-A)...
September 29, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/28959338/implementation-of-plasma-fractionation-in-biological-medicines-production
#18
REVIEW
Kamran Mousavi Hosseini, Mehran Ghasemzadeh
CONTEXT: The major motivation for the preparation of the plasma derived biological medicine was the treatment of casualties from the Second World War. Due to the high expenses for preparation of plasma derived products, achievement of self-sufficiency in human plasma biotechnological industry is an important goal for developing countries. EVIDENCE ACQUISITION: The complexity of the blood plasma was first revealed by the Nobel Prize laureate, Arne Tiselius and Theodor Svedberg, which resulted in the identification of thousands of plasma proteins...
December 2016: Iranian journal of biotechnology
https://www.readbyqxmd.com/read/28958504/rilotumumab-plus-epirubicin-cisplatin-and-capecitabine-as-first-line-therapy-in-advanced-met-positive-gastric-or-gastro-oesophageal-junction-cancer-rilomet-1-a-randomised-double-blind-placebo-controlled-phase-3-trial
#19
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham
BACKGROUND: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine, and to assess potential biomarkers, in patients with advanced MET-positive gastric or gastro-oesophageal junction adenocarcinoma. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 study was done at 152 centres in 27 countries...
September 25, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28958419/workplace-bullying-in-emergency-nursing-development-of-a-grounded-theory-using-situational-analysis
#20
Lisa A Wolf, Cydne Perhats, Paul R Clark, Michael D Moon, Kathleen Evanovich Zavotsky
BACKGROUND: The Institute of Medicine recognizes that the workplace environment is a crucial factor in the ability of nurses to provide safe and effective care, and thus interactions that affect the quality and safety of the work environment require exploration. OBJECTIVES: The purpose of this study was to use situational analysis to develop a grounded theory of workplace bullying as it manifests specifically in the emergency care setting. METHODS: This study used a grounded theory methodology called situational analysis...
September 22, 2017: International Emergency Nursing
keyword
keyword
96295
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"